Oral nicotinamide mononucleotide (NMN) to treat chronic insomnia: protocol for the multicenter, randomized, double-blinded, placebo-controlled trial

What Was Tested

The paper reports a study of NAD+, published as a clinical study.

Secondary outcomes are the score on the Insomnia Severity Index (ISI) and Epworth Sleeping Scale (ESS), the total sleep time (TST), sleep efficiency (SE), sleep latency, and REM sleep latency to assess sleep quality changes.

Why It Was Studied

The treatment of insomnia, which is the most common sleep disorder, includes drug and behavioral treatment, but each treatment measure has its limitations.

Chinese Clinical Trial Registry (chictr.org.cn) ChiCTR2200058001.

Who Took Part

According to the abstract, 400 patients were involved.

The researchers describe a proposal for a multicenter, patient-assessor-blinded, randomized controlled trial with two parallel arms.

All subjects are clinical chronic insomnia patients who meet all inclusion criteria.

How the Study Was Run

The design is described as randomized, placebo-controlled, multicenter and parallel-group.

Random assignment meant chance, not the researchers, decided who got NAD+ and who got the comparison, which limits bias.

Some patients received a placebo instead of NAD+, giving a reference point.

More than one site took part, so the patients came from several places.

Groups ran in parallel: each of the patients stayed in one arm throughout.

All subjects are treated by taking NMN or placebo.

The primary outcome is the score on the Pittsburgh Sleep Quality Index (PSQI).

Subjects are assessed at two time points: baseline and follow-up.

The duration of the clinical trial is 60 days.

What Was Measured

The treatment of insomnia, which is the most common sleep disorder, includes drug and behavioral treatment, but each treatment measure has its limitations.

The subject headings attached to it are Sleep Initiation and Maintenance Disorders, Nicotinamide Mononucleotide, Sleep and Randomized Controlled Trials as Topic.

The authors tagged it with the keywords Chronic insomnia and Nicotinamide mononucleotide (NMN).

What This Means in Plain Language

The paper is a randomized, placebo-controlled and multicenter study of NAD+ in 400 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Trials), a journal based in England.

More context: the NAD+ compound page, all human trials.